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ABSTRACT
Objective: The objective of the present study is to confirm and/or prove the beneficial outcomes from using Brewer’s yeast and Ginger in constipation-
predominant irritable bowel syndrome (IBS-C) subjects compared to placebo.
Methods: A total of 45 patients suffering from IBS-C were enrolled in a double-blind placebo-controlled study as defined by Rome III criteria. Parallel 
groups were randomly assigned in this study: A placebo group, Brewer’s yeast group, and ginger group, taken daily for 20 days. IBS severity scale and 
visual analog scale for IBS (VAS-IBS) were used to assess the severity of pain, abdominal distention, and constipation (IBS-C) subjects. The data were 
measured at 3 times: At 0 time (T0), after 10 days of treatment (T10), and after 20 days of treatment (T20) for the three treatment groups.
Results: Intragroup analysis showed a clinically significant reduction in the symptoms of abdominal pain, distention, and constipation, in the Brewer’s 
yeast group compared to placebo after the 20 days of the study. There was also a significant reduction of abdominal distention and constipation 
symptoms in the ginger group throughout the study.
Conclusion: This study reveals the beneficial effects of Brewer’s yeast and ginger in reducing troublesome gastrointestinal symptoms in subjects with 
IBS-C and holds the promise to use them in IBS-C patient.
Keywords: Irritable bowel syndrome, Constipation-predominant irritable bowel syndrome background, Brewer’s yeast, Ginger.
INTRODUCTION
Irritable bowel syndrome (IBS) is a widespread gastrointestinal 
disorder with symptoms of abdominal pain, discomfort, cramping, 
and alternating bowel habits of constipation and diarrhea [1]. Till now, 
there are no clear causes and there is no diagnostic tool to screen and 
diagnose people with IBS [2]. The treatment mainly concentrates on the 
relief of symptoms to have a normal quality of life [3].
It can be classified into three specific forms: Constipation-predominant 
IBS-C, diarrhea-predominant IBS-D, or mixed symptoms of constipation 
and diarrhea (IBS-M) [4]. Since there are no clear causes, treatment 
focuses on symptoms relief, which can be managed by controlling stress, 
avoiding high-gas foods, exercising, drinking plenty of fluids, get enough 
sleep, and using fiber supplements, antidiarrheal, antispasmodic, and 
antidepressant medications [5,6].
This study concentrates on constipation-predominant IBS-C, which 
can be defined as constipation associated with abdominal pain and 
discomfort that is generally relieved by defecation [7], affects about 
34% of the IBS population [8,9]. Recent studies show that IBS-C is 
associated with higher rates of functional impairment, as compared 
to other subtypes of IBS [10-12]. The use of traditional laxatives was 
unsatisfactory in the treatment of IBS-C [13]. Till now, there is no 
drug therapy that can be used safely and chronically to treat all of the 
symptoms of IBS-C and improves the patient’s health-related quality of 
life [14].
Brewer’s yeast is made from Saccharomyces cerevisiae, which is a 
one-celled fungus. It is used as a nutritional supplement and a source 
of Vitamin B complex, selenium, and chromium and considered 
a probiotic that can help to maintain the proper function of the 
digestive tract [15,16]. It also has been found to ease and reduce 
constipation. It will initially produce gases in the colon and then helps 
with constipation relief and patient comfort [17]. Brewer’s yeast 
increases the good bacteria in the colon and reduces the bad which will 
help in maintaining normal bowel movement [18-20].
On the other hand, ginger is an important traditional herb that has 
been used by ancient Chinese and Indian people [21]. Ginger was used 
primarily for it antiemetic, anti-inflammatory, and analgesic properties 
that have been proven from many previous studies [22]. Furthermore, 
it was found to improve blood circulation, lower blood cholesterol, and 
lower blood glucose and treat migraine headaches [23-25]. It was found 
to facilitate digestion, improve bowel motion, decrease nausea and 
vomiting, and relieve constipation and flatulence [26-29]. Thus, ginger 
could be a beneficial and generally safe medicine that can reduce the 
pain and flatulence and improves bowel activity in IBS-C patients.
This study aimed to perform a randomized placebo-controlled clinical 
trial on IBS-C subjects to confirm and/or prove the beneficial outcomes 
from using Brewer’s yeast and ginger in IBS-C subjects.
METHODS
Study design and population
A total of 45 outpatients with constipation-predominant IBS-C were 
included in this multicenter double-blind controlled study. Parallel 
groups of 15 subjects were randomly assigned in this study: A placebo 
group, 500 mg Brewer’s yeast group and 1 g ginger group, taken daily 
for 20 days. Age of the subjects selected was 18 and more seasoned with 
a physician conclusion of IBS with constipation confirmed by Rome III 
criteria [30].
A self-reported questionnaire, using IBS severity scale (IBS-SS) 
and visual analog scale of IBS (VAS-IBS) were used to assess the 
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severity of pain, abdominal distention, and constipation (IBS-C) 
subjects rated on a 0–100 scale, where 0 = none symptom and 
100 = more severe symptom [31,32]. The data were measured at 
3 times: At 0 time before treatment (T0), after 10 days of treatment 
(T10), and after 20 days of treatment (T20) for the three treatment 
groups. Age of the subjects involved was between 18 and 64 years.
A written informed patient consent was taken from all the volunteers in 
the study. Exclusion criteria were as follows: Pregnant or breastfeeding 
females, the presence of uncontrolled cardiovascular disease, diabetes 
mellitus (type I or II), psychological conditions, renal or hepatic 
sickness, uncontrolled thyroid disease, Parkinson’s disease, previous 
gastrointestinal surgery, allergy to ginger or S. cerevisiae (Brewer’s 
yeast), and exclude patients taking medications that are frequently 
associated with constipation such as contraceptives, proton-pump 
inhibitors, beta-blockers, ACE inhibitors, calcium antagonists, statins, 
diuretics, and barbiturates. Furthermore, avoid patients with gout or 
who are taking monoamine oxidase inhibitors which interact with 
Brewer yeast. In addition, avoid taking laxative drugs for constipation 
such as bisacodyl, psyllium, senna, macrogol, lactulose, sodium 
bicarbonate, sorbitol, prucalopride, and Glauber’s salt. Any of the 
previous factors and conditions was excluded as possible during the 
20 days of study.
Assessment measures
Self-reported questionnaire, using IBS-SS, was used to assess the 
severe abdominal pain and abdominal distension or bloating rated on 
a 0–100 scale. The severity of constipation was assessed using VAS for 
IBS rated from 0 to 100. The data were measured at 3 times: At 0 time 
before treatment (T0), after 10 days of treatment (T10), and after 
20 days of treatment (T20) for the three groups of patients.
Treatment
Patients were randomized to get either the treatment or placebo, once, 
day by day for 20 days of study period. Subjects were submitted to three 
control visits through the span of 20 days at day 0 and two follow-up 
visits at days 10 and 20.
The placebo capsules were prepared to contain brown sugar. Brewer’s 
yeast (S. cerevisiae) 500 mg tablets of Adrien Gagnon Company were 
used in the study. Ginger root powder (Zingiber officinale Roscoe, 
Zingiberaceae) was capsulated in a dose of 1 g daily capsule provided 
by simply organic company.
Statistical analysis
All data are reported as mean ± SD. IBS-SS and VAS of IBS were used to 
assess the severity of pain, abdominal distention, and constipation in 
IBS-C subjects rated on a 0–100 scale, where 0 = none symptom and 
100 = more severe symptom [31,32]. Statistical analysis of data was 
performed using Statistical Analysis System (SAS) - version 9.1 (SAS. 
2010). Two-way ANOVA and least significant differences post hoc test 
were performed to assess significant differences among means. p<0.05 
is considered statistically significant.
RESULTS
A total of 45 subjects with IBS-C were included into this study and were 
successfully randomized to be either in placebo group (n=15) or active 
treatment groups: Brewer’s yeast (n=15) and ginger group (n=15). The 
medications were received daily for 20 days. Data were collected at 
three different times (day zero T0, after 10 days T10, and after 20 days 
T20). When the study begins, all the subjects show a high adherence 
to the treatment. Fig. 1 represents the consort flowchart of the study.
The mean values +SD of the scores, taken from the IBS-SS scale, for the 
abdominal pain and distention and from VAS-IBS scale applied for the 
severity of constipation, are shown in Table 1 for the different groups 
and times. The results revealed no statically significant differences at 
time zero for all groups with all symptoms measured, at this time, no 
treatment has been received yet.
Intergroup analysis of pain measures revealed a statistically significant 
reduction of pain in the Brewer’s yeast group at the different times 
(T0 = 40.26±3.66, T10 = 31.80±2.73, and T20 = 26.66±2.70; p<0.05), 
whereas the reduction in the ginger group not quite significant 
(T0 = 39.60±3.29, T10 = 36.06±3.46, and T20 = 31.73±3.21; p<0.05). 
The placebo group shows no statistically significant difference as 
shown in Table 1. Furthermore, if T20 results were compared, for the 
pain measures, at the three treatment groups, a significant reduction 
occurs mainly in the Brewer’s yeast group (placebo = 37.66±2.89, 
Brewer’s yeast = 26.66±2.70, and ginger = 31.73±3.21; p<0.05). 
Intergroup analysis of abdominal distention measures revealed a 
statistically significant reduction of distention in the Brewer’s yeast 
group between T0 and the times T10 and T20 (T0 = 69.80±3.73, T10 
= 53.53±3.37, and T20 = 45.00±3.21; p<0.05), similar significant 
reduction was in ginger group (T0 = 68.73±3.68, T10 = 53.53±3.37, and 
T20 = 50.00±2.88; p<0.05). The placebo group shows no statistically 
significant difference as shown in Table 1. Furthermore, if T20 results 
were compared, for the abdominal distention measures, at the three 
treatment groups, a significant reduction occurs in the Brewer’s 
yeast and ginger groups compared to placebo (placebo = 59.33±2.43, 
Brewer’s yeast = 45.00±3.21, and ginger = 50.00±2.88; p<0.05).
Intergroup analysis for the constipation severity measures revealed 
a small statistically reduction in constipation severity in the placebo 
group at T0 compared to times T10 and T20 but still severe on the VAS-
IBS scores (T0 = 75.60±2.43, T10 = 66.93±1.96, and T20 = 65.86±2.64; 
p<0.05). Analysis also revealed a statistically significant reduction 
of constipation severity in the Brewer’s yeast group between T0 and 
the times T10 and T20 (T0 = 67.80±3.72, T10 = 48.13±3.22, and 
T20 = 42.93±3.28; p<0.05). Similar significant reduction was in ginger 
group (T0 = 70.66±3.09, T10 = 55.26±3.03, and T20 = 49.13±2.73; 
Fig. 1: Consort flow diagram
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p<0.05). Furthermore, if T10 results were compared, for the constipation 
severity measures, at the three treatment groups, a significant reduction 
occurs in the Brewer’s yeast and ginger groups compared with placebo 
(placebo = 66.93±1.96, Brewer’s yeast = 42.93±3.28, and ginger = 
55.26±3.03; p<0.05), similar reductions at T20 (placebo = 65.86±2.64, 
Brewer’s yeast = 45.00±3.21, and ginger = 49.13±2.73; p<0.05).
DISCUSSION
Constipation and IBS are common complaints and challenges nowadays, 
especially for older adults. The available therapies provide satisfaction 
in <40% of IBS population [33]. Lifestyle modification, secondary and 
medication-induced causes, and non-pharmacologic treatment should 
be the first step to avoid unnecessary drug therapy [8]. Many factors 
can increase the risk of IBS, in general, and IBS-C, in particular, such 
as age, diet type (low fiber, high in saturated fat, and fermentable 
carbohydrate), being obese, low exercise fitness, being a woman, and 
having psychosocial and environmental stress [34-37].
Although the pathogenesis of IBS still unclear, evidence proved a 
strong relation with stress, abnormal intestinal motility, diet, and gut 
microbiota [38]. Stress was found to be an important factor that can 
disrupt normal bowel movements and contribute to IBS symptoms and 
constipation [39]. Thus, in the placebo groups in this current study, 
a number of patients show improvements in the IBS-C symptoms, 
despite having no active treatment. This indicates the relation between 
the psychological state of patient and IBS symptoms. In the previous 
years, the importance of psychosocial and environmental stressors on 
the pathogenesis IBS has researched widely [39]. Stress may influence 
diverse physiologic elements of the gastrointestinal tract including 
gastric secretions, gastrointestinal motility, mucosal penetrability, 
visceral sensitivity, and mucosal blood flow [40,41]. Furthermore, 
stress has been shown to have a strong effect on gut microbiota. It has 
been found that catecholamines could change the growth, motility, and 
virulence of gut bacteria which can play an important role in IBS [42,43].
Gastrointestinal microbiota and probiotics have been proved 
to be beneficial to the host by exerting various effects such as 
immunomodulation, competition with pathogens for nutrients and 
thus growth suppression, and production of antibacterial toxin 
(bacteriocins) [44]. Probiotics also proved to have a positive impact 
on the gut–brain axis and thus could be named “psychobiotics” [45]. 
In a 1-month human study, probiotics have found to alter mental 
status compared to placebo, using functional magnetic resonance 
imaging [46]. Many studies have linked the abundance of bacteria in 
the gut with IBS occurrence. This relationship is substantially complex 
and includes a number of mechanisms which remain to be not fully 
clarified [47,48]. The benefits from using probiotics in alleviating 
IBS symptoms have been demonstrated by many studies, but more 
researches have to be conducted to prove the clinical efficacy and 
mechanistic basis of probiotic in the management of IBS.
S. cerevisiae is a yeast species that has been contributory to 
winemaking, baking, and brewing [15]. Brewer’s yeast tablets are made 
from S. cerevisiae species. This probiotic has been researched in IBS 
patients and shows advantageous properties to IBS symptoms. Four 
previous, randomized clinical trials have studied the effects of S. cerevisiae 
on IBS and showed that S. cerevisiae could alleviate IBS symptoms such 
as abdominal pain, abdominal distention, and constipation [18-20,49]. 
This current study strengthens and confirms the beneficial effects of 
S. cerevisiae on the symptoms of IBS-C. There was a significant reduction 
in the gastrointestinal symptoms measured including pain, distention, 
and constipation severity. The results were remarkable, especially after 
20 days of the treatment. The abdominal pain was decreased 13.6 points 
on IBS-SS scale (33.8% reduction). The abdominal distention or bloating 
decreased 24.8 points on IBS-SS scale (35.5% reduction). Constipation 
decreased 24.9 points on VAS-IBS scale (36.7% reduction).
Ginger is a safe, widely available, and low-cost herb that has been proved to 
have many useful antiemetics, anti-inflammatory, sedative, and analgesic 
properties, in addition to its beneficial effects on blood circulation [22]. 
Concerning the gastrointestinal diseases, ginger was found to be valuable 
in alleviating many GIT symptoms such as pain, bloating, constipation, 
nausea and vomiting, and improving gut motility [26,27,29]. For these 
beneficial GIT outcomes, it has been studied in IBS and IBS-C subjects and 
proved to be a useful future medicine [28,29]. This current study agrees 
with other previous studies and confirms the useful effects of ginger in 
the management of IBS-C patients and alleviating the symptoms. There 
was a clinically significant reduction in the abdominal distention and 
constipation severity variables of IBS-C. The pain was reduced in about 
19.9%, abdominal distention 27.3%, and constipation 30.5%, throughout 
the 20 days of the study.
As a conclusion, Brewer’s yeast and ginger are two promising, 
multiadvantageous, natural, widely available, and low-cost future 
medications for IBS-C patients. These compounds need to be studied 
extensively, on the bases of their mechanisms and whole effects on the 
body, to reach the proper cure for IBS-C.
CONCLUSION
This study reveals the beneficial effects of Brewer’s yeast and ginger in 
reducing troublesome gastrointestinal symptoms in subjects with IBS-C 
and holds the promise to use them in IBS-C patient.
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Table 1: Primary outcomes in placebo, Brewer’s yeast, and ginger groups measured by IBS‑SS and VAS‑IBS scores, as mean value+SD, at 
three different times
Measures Treatment groups T 0 T 10 T 20
Abdominal pain (IBS-SS) Placebo A42.46±2.94a A36.33±2.85a A37.66±2.89a
Brewer’s yeast A40.26±3.66a AB31.80±2.73a B26.66±2.70b
Ginger A39.60±3.29a A36.06±3.46a A31.73±3.21ab
LSD 8.6825
Abdominal distention (IBS-SS) Placebo A66.33±2.72a A61.06±2.62a A59.33±2.43a
Brewer’s yeast A69.80±3.73a B53.53±3.37a B45.00±3.21b
Ginger A68.73±3.68a B52.73±2.48a B50.00±2.88b
LSD 8.5481
Constipation severity (VAS-IBS) Placebo A75.60±2.43a B66.93±1.96a B65.86±2.64a
Brewer’s yeast A67.80±3.72a B48.13±3.22b B42.93±3.28b
Ginger A70.66±3.09a B55.26±3.03b B49.13±2.73b
LSD 8.2465
Values are expressed as mean±standard deviation. Means with a different capital letter in the same row significantly different (p<0.05). Means with a different small 
letter in the same column significantly different (p<0.05). LSD: Least significant differences (T0 [before treatment], T10 [after 10 days of treatment], and T20 [after 
20 day of treatment])
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